Objective-We have recently reported that recombinant human soluble thrombomodulin (rTM) counteracted capillary leakage associated with engraftment, as well as sinusoidal obstructive syndrome after hematopoietic stem cell transplantation. These observations prompted us to explore whether rTM possessed cytoprotective effects on endothelial cells. Methods and Results-Exposure of human umbilical vein endothelial cells to rTM induced expression of antiapoptotic protein myeloid leukemia cell-1 through the activation of extracellular signal-regulated kinase in these cells. Additional studies found that exposure of human umbilical vein endothelial cells to cyclosporine A and FK506, an immunosuppressant used for the individuals receiving hematopoietic stem cell transplantation, induced apoptosis, which was attenuated when human umbilical vein endothelial cells were exposed to these agents in the presence of rTM. Further studies using deletion mutants of thrombomodulin (TM) identified that the epidermal growth factor domain of TM possessed cytoprotective effects. A single nucleotide substitution at codon 376 or 424 of TM, which impairs the ability of TM to produce activated protein C or bind to thrombin, respectively, did not hamper the cytoprotective effects of TM, which suggested that cytoprotective effects of rTM were distinctive from those of activated protein C. Conclusion-TM may be useful for prevention, as well as treatment of endothelial cell damage after hematopoietic stem cell transplantation. (Arterioscler Thromb Vasc Biol. 2012;32:2259-2270.)
T hrombomodulin (TM) is a glycosylated type I transmembrane molecule of 557 amino acids with multiple domains. The molecule consists of an NH2-terminal lectinlike region (D1) followed by 6 tandem epidermal growth factor (EGF)-like structures (D2), an O-glycosylation site-rich domain (D3), a transmembrane domain (D4), and a cytoplasmic tail domain (D5). 1 TM is ubiquitously expressed on endothelium and bound to thrombin, forming a 1:1 complex via an EGF-like domain and acting as an anticoagulant. 2 In addition, the thrombin-TM complex activates protein C to produce activated protein C (APC), which inactivates factors VIIIa and Va in the presence of protein S, thereby inhibiting further thrombin formation. 3 TM also possesses anti-inflammatory activity through both protein C-dependent and protein C-independent pathways. The lectin-like domain of TM binds to and inactivates high-mobility group box 1 protein, 4 a proinflammatory cytokine that stimulates production of inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-α via toll-like receptor 4 and receptors for advanced glycation end products. Other group also demonstrated that the lectin-like domain of TM played a critical role to protect lungs from tissue-damaging proinflammatory responses after ischemia-reperfusion. 5 On the other hand, the thrombin-binding domain of TM was shown to possess the ability to inhibit cancer cell metastasis, which was dependent on cancer cell-associated tissue factor expression. 6 Thus, TM is a multifunctional molecule.
Recombinant human soluble thrombomodulin (rTM) comprises the active, extracellular domain of TM, and inactivates coagulation. A recent phase III trial comparing the efficacy and safety between rTM and lowdose heparin showed that rTM significantly improved disseminated intravascular coagulation associated with hematological malignancies or infections. 7 Use of rTM for the treatment of disseminated intravascular coagulation was approved in Japan in 2008. We have recently rescued individuals with disseminated intravascular coagulation complicated by a variety of underling diseases, including transplantation-associated microangiopathy 8 and sinusoidal obstructive syndrome, as well as engraftment syndrome after hematopoietic stem cell transplantation, 9, 10 in which endothelial cell damage, as evidenced by elevated serum levels of soluble TM, caused by immunosuppressant agents such as cyclosporine (CsA), cytotoxic chemotherapy, and exaggerated production of inflammatory cytokines is considered to be playing a critical role. Surprisingly, administration of rTM potently counteracted bodyweight gain complicated by sinusoidal obstructive syndrome and engraftment syndrome, 9, 10 which prompted us to hypothesize that TM could possess cytopotective effects in the endothelium. To verify our hypothesis, we have performed in vitro experiments using human umbilical vein endothelial cells (HUVECs) and found that rTM induced expression of antiapoptotic protein myeloid cell leukemia-1 (Mcl-1) in association with activation of extracellular signal-regulated kinase (ERK). In addition, rTM protected HUVECs from CsA-induced apoptosis.
Materials and Methods

Cells
HUVECs and COS-1 cells were purchased from Lonza Walkersville Inc (Walkersville, MD) or American Type Culture Collection (Manassas, VA), respectively. HUVECs were cultured with EGM endothelial cell growth medium (Lonza Walkersville Inc) supplemented with 2% fetal bovine serum. Neither thrombin nor protein C was supplemented to culture media.
Reagents
The mitogen-activated protein kinase inhibitor AZD6244 and rTM were provided by AstraZeneca Pharmaceuticals Ltd (Macclesfield, UK) and Asashi Kasei Pharma (Tokyo, Japan), respectively. CsA, FK506, and interleukin-1β were purchased from Sigma Chemical (St. Louis, MO). Human recombinant hirdin and vascular endothelial growth factor were purchased from ProSpec-Tany Technogene Ltd (Rehovot, Israel) and PeproTech (Rocky Hill, NJ), respectively.
Proliferation Assays
HUVECs (5×10 3 cells) were cultured in a 96-well plate for 24 hours in the presence of rTM (3-100 ng/mL). Bromodeoxyuridine (10 μmol/L/well) was added and incubated for an additional 4 hours. The quantity of bromodeoxyuridine incorporated into the newly synthesized DNA was assessed in accordance with the manufacturer's protocol (Roche, Mannheim, Germany).
Apoptosis Assays
The ability of a calcineurin inhibitor and rTM to induce apoptosis in HUVECs was measured using the annexin V-fluorescein isothiocyanate apoptosis detection kit (Pharmingen, Inc, San Diego, CA), as previously described. 11 Terminal deoxynucleotidyl transferase dUTP nick end labeling was also used to detect DNA fragmentation caused by calcineurin inhibitors in HUVECs, according to the manufacturer's instructions (Roche).
In Vitro Vascular Tube Formation Assay
To evaluate the effect of rTM on endothelial tube formation in vitro, HUVECs were plated into growth factor-reduced Matrigel (BD Biosciences, Bedford, MA) precoated 24-well plate at a density of 2.5×10 4 cells per well and incubated with control diluent, rTM (10-100 ng/mL), or vascular endothelial growth factor (20 ng/mL) as a positive control. After 8 hours, the endothelial cell-derived tube-like structure was visualized under an inverted microscope and photographed at a magnification of ×40. The tube length in 5 randomly chosen fields from each well was measured using NIH ImageJ software (Wayne Rasband, NIH, Bethesda, MA) and compared with the control. The angiogenic index was calculated as the number of branch points in a field for a particular treatment. Five different fields were counted for each treatment, and the number of branch points was averaged.
Immunocytochemistry
HUVECs were stained with anti-TM (Abcam, Cambridge, UK) and anti-mouse horseradish peroxidase-linked secondary antibodies (Cell Signaling Technology, Beverly, MA) and examined under light microscope.
ELISA
Culture media of HUVECs was collected and applied to ELISA kit to measure the concentration of TM according to the manufacturer's protocol (Abcam).
Western Blot Analysis
Western blot analysis was performed as described previously. 12 The membrane was probed sequentially with the antibodies. Anti-p-ERK (T202/Y204) (Cell Signaling Technology, 9101), anti-ERK (Cell Signaling Technology, 9102), AKT (Cell Signaling Technology, 9272), p-AKT (Ser473) (Cell Signaling Technology, 9271), anti-STAT 5 (C-17) (Santa Cruz Biotechnology, sc-835), and anti-p-STAT 5 (Tyr694) (Cell Signaling Technology, 9351), anti-S6K (Cell Signaling Technology, 2217), anti-p-S6K (Ser235/236) (Cell signaling Technology, 4856), anti-4E-BP1 (Cell Signaling Technology, 9644), anti-p-4E-BP1(Thr37/46) (Cell Signaling Technology, 2855), antic-Jun N-terminal kinase (JNK) (Santa Cruz Biotechnology, sc-474), anti-p-JNK (Tyr183/185) (Cell Signaling Technology, 9251), anti-p38 (Santa Cruz Biotechnology, sc-535G), anti-p-p38 (Tyr180/182) (Cell Signaling Technology, 9216), anti-eNOS (Cell Signaling Technology, 9572), anti-p-eNOS (Ser1177) (Cell Signaling Technology, 9570), anti-Mcl-1 (Santa Cruz Biotechnology, sc-819), anti-B-cell lymphoma-2 (Bcl-2) (Santa Cruz Biotechnology, sc-509), anti-B-cell lymphomaextra large (Bcl-xL) (Santa Cruz Biotechnology, sc-2764), anti-PARP (Cell signaling Technology, 9532), anti-caspase 3 (Cell Signaling Technology, 9662), anti-TM (Abcam), and anti-GAPDH (Abcam) antibodies were used. Band intensities were measured by ImageJ software (Wayne Rasband, NIH).
RNA Isolation and Reverse Transcription-Polymerase Chain Reaction
RNA isolation and cDNA preparation were performed as described previously. 13 We measured the expression of 18S for normalization as described previously. 13 Real-time reverse transcription-polymerase chain reaction (RT-PCR) was carried out using Power SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK) as described previously. 13 Primers for PCR to detect Mcl-1 (5′-GGGAAGCTATGGAGGAGGAC-3′ and 5′-ATGACTTGCCTGGCTACTGG-3′), TM (5′-CACAGGTGCCAG-ATGTTTTG-3′ and 5′-AACCGTCGTCCAGGATGTAG-3′), and 18s (5′-AAACGGCTACCACATCCAAG-3′ and 5′-CCTCCAATGGAT-CCTCGTTA-3′) were synthesized by Sigma. PCR conditions for all genes were as follows: 95°C initial activation for 10 minutes followed by 40 cycles of 95°C for 15 s and 60°C for 60 s, and fluorescence determination at the melting temperature of the product for 20 s on an ABI PRISM 7000 (Applied Biosystems).
Vascular Permeability Assay
Effects of CsA and rTM on vascular permeability were measured by the vascular permeability assay kit (Millipore, Billerica, MA). Briefly, HUVECs were seeded onto collagen-coated inserts and cultured for 72 hours to allow them to be confluent. After 24 hours of starvation, cells were treated with either CsA, rTM, or a combination of both for 12 hours, and then fluorescein isothiocyanate-dextran was added on top of the cells, allowing it to permeate through the cell monolayer. The extent of permeability was determined by measuring the fluorescence of the plate well solution.
NO Production
NO production in HUVECs was measured as nitrite (NO 2 -) accumulation in the culture medium, in which an equal volume of Griess reagents was added following the manufacturer's instructions (Promega, Madison, WI). After 10 minutes of incubation, the absorbance of supernatants was measured by a spectrometer (BS1000 Spectra Count) at 570 nm.
Small Interfering RNA
Control small interfering RNA (siRNA) and an siRNA against Mcl-1 were purchased from Santa Cruz Biotechnology and Sigma Chemicals, respectively.
Blockade of APC Signaling
To prevent APC from binding to endothelial protein C receptor (EPCR) and to inhibit APC-mediated signaling, an anti-EPCR antibody, RCR-252 (Hycult biotech, Uden, The Netherlands), was used.
Plasmids
Human MCL1 (NM_021960) was synthesized and cloned into pTracer-CMV/Bsd expression vector (Invitrogen, Carlsbad, CA). Expression plasmid pSV2TMJ2, which encodes the entire TM, was provided from Asashi Kasei Pharma (Tokyo, Japan). D123 and various types of TM mutants, including D12, D2, D1, E456, E45, E456-I424A, D123-I424A, and D123-F376L, are described in detail elsewhere [14] [15] [16] and cloned into the FLAG-TEV-tagged pcDNA3.1/ V5-His-TOPO expression vector (Invitrogen).
Transfections
HUVECs were transiently transfected with an siRNA (300 nmol/L) or a vector (2 μg) by Amaxa electroporator Nucleofector II (Wako Pure Chemical Industries, Ltd, Osaka, Japan), using the Nucleofector Kit V (program U-001), as described previously. 17 The preliminary experiments using the green fluorescence protein-expressing vector found that the efficacy of transfection with this program was ≈70% with ≈70% cell viability, as measured by fluorescence-activated cell sorter and annexin V/propidium iodide staining, respectively (data not shown).
Production of Mutant TM Proteins
COS-1 cells were transfected with 2 μg of each TM expression vector using FUGENE transfection reagent (Promega, Tokyo, Japan). After 48 hours of culture, the culture supernatant was collected and centrifuged at 400g for 5 minutes. His-tagged mutant TM proteins were purified using the His-tagged protein purification kit (MBL, Nagoya, Japan) according to the manufacturer's instruction. Protein concentrations were determined by the Bradford assay using BSA as a standard. The purified proteins were analyzed by 12.5% SDS-PAGE and detected by Coomassie blue staining and with an anti-V5 antibody (Invitrogen). The molecular weight of mutant TM was assessed using KODAK 1D image analysis software (Eastman Kodak Co., Rochester, NY).
Protein C Activation Assay
TMD123 (2.5 nmol/L) or TM mutants were incubated with 200 nmol/L protein C and 1.4 nmol/L thrombin (60 minutes at 37°C, 1.2 mL total volume) in Eppendorf tube to generate APC. The amount of APC generated was measured by monitoring the hydrolysis of the chromogenic substrate, S-337, at 405 nm in a microplate reader at 5-minute intervals for 60 minutes, as described previously. 18
Murine Angiogenesis Assay
To assess the angiogenetic effects of rTM in vivo, growth factor-reduced Matrigel (0.5 mL) containing heparin (40 U/mL) with control diluent, rTM (30 or 100 ng/mL), or vascular endothelial growth factor (20 ng/mL) was subcutaneously injected into C57BL6 mice (6-week-old female) near the abdominal midline. Four days after implantation, mice were euthanized, and the Matrigel plugs were surgically removed and photographed. For histological analysis in Matrigel plugs, immunohistochemical staining of CD31was performed with a Ventana DISCOVERYTM autostainer system (Ventana Japan, Osaka, Japan) as described previously. 19 Anti-mouse CD31 antibody (Santa Cruz Biotechnology) was used. The same specimens were used for hematoxylin and eosin staining.
In Vivo Endothelial Cell Damage in Murine Model
C57BL6 mice (6-week-old female) were treated with either FK506 (5 mg/kg) or control diluent every day for 7 days by intraperitoneal injection. Either rTM (0.5 mg/kg) or control diluent was given to mice every another day by intraperitoneal injection for 7 days. At the end of experiments, mice were euthanized and blood was collected. Plasma was separated by centrifugation, and the plasma levels of murine TM, a marker of endothelial cell damage, were assessed by murine TM ELISA kit (Uscn Life Science, Tokyo, Japan) following the manufacturer's instructions. At the same time, kidneys and livers were removed from mice and mashed to make a single cell. These cells were stained with an anti-CD31antibody (Biolegend, San Diego, CA), and positive cells were isolated by sorting using JSAN (Bay bioscience, Ltd, Kobe, Japan). RNA was extracted and subjected to real-time RT-PCR to measure the levels of murine Mcl-1.
Statistical Analysis
Statistical analysis was performed to assess the difference between 2 groups under multiple conditions by 1-way ANOVA, followed by Bonferroni multiple comparison tests using PRISM statistical analysis software (GraphPad Software, Inc, San Diego, CA).
Results rTM Protects HUVECs From CsA-Induced Apoptosis
We first examined whether CsA, a calcineurin inhibitor used for individuals who received hematopoietic stem cell transplantation to prevent graft-versus-host disease, induced apoptosis in HUVECs. Exposure of HUVECs to CsA (2 or 4 mg/mL) for 48 hours induced either 27% or 40% of cells, respectively, to become annexin V staining positive, indicating the induction of apoptosis ( Figure 1A) . HUVECs abundantly expressed TM on their cell surface, which was apparently decreased after their exposure to CsA (2 or 4 mg/mL for 48 hours), as measured by immunocytochemistry ( Figure 1B ). In parallel, terminal deoxynucleotidyl transferase dUTP nick end labeling assay was used, showing induction of DNA fragmentation, a feature of apoptosis, in HUVECs after exposure to CsA ( Figure 1C ). Real-time RT-PCR confirmed the downregulation of TM caused by CsA at both mRNA and protein levels ( Figure 1D and 1E ). In parallel with the loss of expression of TM in HUVECs, the concentration of TM in culture media was elevated when HUVECs were cultured in the presence of CsA ( Figure 1F ), suggesting that TM on their cell surface was cleaved when these cells underwent apoptosis. These in vitro results mirror clinical observations that serum levels of TM were elevated in individuals with endothelial cell injury. 20 We next examined whether rTM possessed cytoprotective effects in HUVECs. Interestingly, when HUVECs were cultured in the presence of both CsA (2 or 4 mg/mL) and rTM (30 ng/mL) for 48 hours, the population of apoptotic cells caused by CsA was decreased by ≈50% ( Figure 1G) . Similarly, FK506 (4 or 8 μg/mL, 48 hours), another calcineurin inhibitor, also induced apoptosis in these cells, which was attenuated in the presence of rTM (30 ng/mL) (data not shown). As a consequence of apoptosis, vascular permeability was profoundly increased after exposure of HUVEC monolayer to CsA (4 mg/mL, 24 hours), which was significantly blocked in the presence of rTM (30 ng/mL) ( Figure 1H ). We explored whether the cytoprotecive effects of rTM were limited to calcineurin inhibitor-caused endothelial cell damage. Notably, rTM (30 ng/mL) effectively blocked interleukin-1β-mediated apoptosis and vascular permeability of HUVEC monolayer ( Figure  1G and 1H).
rTM Counteracts With CsA-Induced Dephosphorylation of Endothelial Isoform of NO Synthase
NO produced by endothelial isoform of NO synthase plays an essential role in the regulation of vascular function. CsA is known to dephosphorylate endothelial NO synthase and decrease the production of NO in endothelial cells. 21 Intriguingly, rTM (30 ng/mL) completely counteracted CsAmediated dephosphorylation of endothelial NO synthase and increased production of NO in HUVECs ( Figure I in the online-only Data Supplement), suggesting the potential role of rTM to restore impaired vascular function.
rTM Stimulates Angiogenesis In Vitro and In Vivo
We also examined the effects of rTM on the proliferation of HUVECs. Exposure of HUVECs to rTM (3-100 ng/mL) stimulated their proliferation in a dose-dependent manner as measured by bromodeoxyuridine incorporation assay (Figure 2A ). The potential role of rTM to stimulate angiogenesis was examined in vitro and in vivo. rTM (30-100 ng/mL) apparently stimulated vascular tube formation of HUVECs in vitro ( Figure 2B ). Measurement of tube length and counting the number of branch points clearly showed the proangiogenic potential of rTM ( Figure 2C and 2D ). Furthermore, Matrigel plugs containing rTM (30 or 100 ng/mL) potently stimulated angiogenesis in C57BL6 mice (Figure 2E-2G ).
rTM Upregulates Mcl-1 Via ERK Signaling
Further experiments explored the molecular mechanisms by which rTM protected HUVECs from CsA-induced apoptosis. We focused on well-known prosurvival signal pathways. Western blot analysis with a variety of antibodies against intracellular signal transduction pathways as well as antiapoptotic proteins was used. Importantly, exposure of HUVECs to rTM for 24 hours increased the levels of phosphorylated forms of ERK in parallel with the upregulation of Mcl-1 in these cells in a dose-dependent manner ( Figure 3A and Figure Further experiments found that exposure of HUVECs to CsA (2 or 4 mg/mL) dephosphorylated ERK in association with decreased levels of Mcl-1, which was completely abrogated in the presence of rTM (30 ng/mL) ( Figure 3E ).
Forced Expression of Mcl-1 Rescues HUVECs From CsA-Mediated Apoptosis
To explore the role of Mcl-1 in cytoprotection in HUVECs, we first overexpressed Mcl-1 in HUVECs by using an expression vector and exposed these cells to CsA. Forced expression of Mcl-1 attenuated CsA-induced apoptosis of HUVECs by approximately half compared with control vector expressing HUVECs, as assessed by annexin V staining ( Figure 4A ). Western blot analysis also confirmed the cytoprotective effects of Mcl-1, as forced expression of Mcl-1 in HUVECs hampered CsA-induced cleavage of caspase 3 and poly ADP ribose polymerase, a marker of apoptosis ( Figure 4B ).
Depletion of Mcl-1 Counteracts the Ability of rTM to Protect HUVECs From CsA-Mediated Apoptosis
We next knocked down Mcl-1 in HUVECs by using an siRNA and then exposed these cells to either CsA (2 or 4 mg/mL), rTM (30 ng/mL), or a combination of both. The Mcl-1 siRNA effectively blocked rTM-induced (30 ng/mL) upregulation of Mcl-1 in HUVECs ( Figure 4C ). On the other hand, control siRNA was not able to attenuate the upregulation of Mcl-1 after exposure to rTM (30 ng/mL) ( Figure 4C ). Interestingly, when Mcl-1 was downregulated by an siRNA, HUVECs became apoptotic and were more susceptible to CsA-mediated apoptosis than control siRNAtransfected HUVECs ( Figure 4D ). Importantly, rTM (30 ng/mL) was no longer able to protect HUVECs from CsAmediated apoptosis when induction of Mcl-1 was blocked by an siRNA (Figure 4D ), confirming the critical role of Mcl-1 in rTM-mediated cytoprotection of HUVECs.
Use of rTM Alleviates Endothelial Cell Damage Caused by FK506 in C57BL6 Mice
Furthermore, we examined whether use of rTM alleviated endothelial cell damage caused by FK506 in C57BL6 mice. Treatment of mice with FK506 (5 mg/kg for 7 days) increased the plasma levels of TM by ≈4-fold compared with control diluent-treated mice, indicating the endothelial cell damage in FK506-treated mice. Importantly, simultaneous administration of rTM (0.5 mg/kg every other day for 7 days) significantly decreased plasma levels of TM in FK506-treated mice ( Figure 5A ). Kidneys and livers were removed from mice treated with either FK506, rTM, or a combination of both, and levels of Mcl-1 in endothelial cells in these organs were measured by real-time RT-PCR. Use of rTM (0.5 mg/kg every other day for 7 days) potently increased the levels of Mcl-1 in murine endothelial cells in kidneys and livers. On the other hand, treatment of mice with FK506 alone decreased levels of Mcl-1 by approximately half in endothelial cells, and when mice were treated with combination of FK506 and rTM, FK506-induced downregulation of Mcl-1 was completely counteracted ( Figure 5B ), suggesting the cytoprotective effects of rTM in vivo.
rTM-Mediated Induction of Mcl-1 Is Independent of Thrombin/APC
To elucidate the domain of TM which mediates induction of Mcl-1, a series of TM mutants ( Figure 6A ) were overexpressed in COS-1 cells, and proteins were purified ( Figure 6B and 6C). The molecular weight of each mutant TM protein was determined by KODAK 1D image analysis software (data not shown). HUVECs were exposed to a series of equal amount of mutant TM protein (17.45 fmol) for 24 hours, and levels of Mcl-1 were monitored by Western blot analysis ( Figure 6D ). The domain 1 of TM (TMD1) alone was not able to induce expression of Mcl-1 in HUVECs ( Figure 6D ). On the other hand, the domain 1 together with domain 2 (TMD12) as well as domain 2 (TMD2) alone induced expression of Mcl-1 ( Figure 6D) . Interestingly, the fourth through sixth EGF-like domains form NH 2 terminus of TM (TME456), and the fourth and fifth EGF domains of TM (TME45) potently induced expression of Mcl-1, and their induction was greater than that mediated by TMD2 ( Figure 6D) . Notably, induction of Mcl-1 was associated with phosphorylation of ERK ( Figure  6D ). We further examined whether TM-mediated induction of Mcl-1 was dependent on APC. The TMD123-F376L mutant that cannot fully act as a cofactor for protein C activation 14 was as effective as wild-type TMD123 to induce Mcl-1 in HUVECs ( Figure 6D ). Furthermore, both TMD123-I424A and TME456-I424A, which cannot fully bind to thrombin, 15 and respective wild-type TM proteins similarly induced expression of Mcl-1 in HUVECs ( Figure 6D) . The protein C activation assay confirmed that the ability of TMD123-F376L and TME456-I424A to generate APC was severely impaired, as the amounts of APC generated by TMD123, TMD123-F376L, and TME456-I424A was 601, 7.02, and 0.75 U/mL, respectively (figure not shown). Furthermore, exposure of HUVECs to a blocking antibody for EPCR, to which APC binds, and human recombinant hirudin, an inhibitor of thrombin, did not hamper the ability of rTM to induce expression of C57BL6 mice (n=5) were treated with either FK506 (5 mg/kg) or control diluent every day for 7 days by intraperitoneal injection. Either rTM 0.5 mg/kg or control diluent was given to mice every other day by intraperitoneal injection for 7 days. At the end of experiments, mice were euthanized and blood was collected. Plasma was separated by centrifugation, and the plasma levels of murine TM were assessed by murine TM ELISA kit. B, Real-time reverse transcription-polymerase chain reaction (RT-PCR). Kidneys and livers were removed from mice and mashed to make a single cell. These cells were stained with an anti-CD31antibody, and positive cells were isolated by sorting. RNA was extracted and subjected to real-time RT-PCR to measure the levels of murine myeloid leukemia cell-1 (Mcl-1). Transcripts of thrombomodulin (TM) were normalized according to the amount of 18S transcript.
Mcl-1 in conjunction with phosphorylation of ERK in these cells ( Figure 6E and 6F) . These observations suggested that cytoprotective effects of TM were independent of APC.
Discussion
The present study, for the first time, demonstrated the cytoprotective effects of TM both in vitro and in vivo and verified the intracellular signal transduction pathway that TM stimulated; rTM increased the levels of antiapoptotic protein Mcl-1 via ERK signaling and protected HUVECs from calcineurin inhibitor-induced apoptosis (Figures 1, 3 , and 4). When Mcl-1 was depleted by an siRNA, rTM was not able to protect HUVECs from cytotoxity caused by CsA ( Figure 4C and 4D ). On the other hand, forced expression of Mcl-1 in HUVECs rescued these cells from rTM-mediated apoptosis ( Figure 4A and 4B) . These observations indicate the important role of Mcl-1 in cytoprotective effects mediated by TM. We have recently shown that downregulation of Mcl-1 was critical in the mitogen-activated protein kinase inhibitor-induced apoptosis of acute myeloid leukemia. 22 In addition, elevated levels of Mcl-1 were associated with drug resistance against a variety of types of chemotherapeutic agents, including the inhibitor of an Fms-like tyrosine kinase 3 and a Bcl-2 antagonist in acute myeloid leukemia and malignant lymphoma cells, respectively. 23, 24 These observations reinforce the important role of Mcl-1 in the cytoprotection of normal as well as malignant cells.
Genetical forced expression of Mcl-1 was not able to fully rescue HUVECs from CsA-mediated apoptosis ( Figure 4A and 4B). Exposure of HUVECs to rTM (30 ng/mL) for 48 hours increased the levels of Bcl-2 and Bcl-xL ( Figure 3A) . These antiapoptotic proteins are also involved in the cytoprotective function of rTM in HUVECs.
Thrombin-TM complex produces APC, which is known to possess the cytoprotective function. APC binds to EPCR and activates protease-activated receptor-1 on endothelial cells, leading to alteration of gene expression involved in apoptosis. 25 For example, microarray identified the antiapoptotic molecule Bcl-2 as an upregulated gene in HUVECs after exposure to human recombinant APC. 25 In addition, the investigators found that human recombinant APC protected HUVECs from apoptosis caused by staurosporine, a potent inducer of the cell death pathway. 25 Similar to the present study, APC or the agonist of protease-activated receptor-1 activated ERK signaling in HUVECs. 26 However, the cytoprotective effect mediated by TM was distinct from that produced by APC, as the blocking antibody against EPCR to which APC binds did not affect the ability of rTM to increase levels of phosphorylated-ERK and Mcl-1 ( Figure 6E ). Furthermore, a series of mutant recombinant TM with reduced capability to interact with thrombin and protein C similarly induced expression of Mcl-1 in HUVECs ( Figure 6D) .
The present study showed that rTM stimulated angiogenesis both in vitro and in vivo (Figure 2) . Similarly, TMD23 stimulated angiogenic potential of early endothelial progenitors through activation of Akt signaling. 27 On the other hand, TMD1 inhibited angiogenesis through interaction with Lewis Y antigen. 28 TMD1 dephosphorylated ERK and decreased levels of Mcl-1 in HUVECs ( Figure 6D ). TMD1 possesses the distinct function in endothelial cells from other domains of TM.
TMD2 more potently induced Mcl-1 in HUVECs than TMD12 and TMD123 ( Figure 6D ). Intriguingly, TMD1 appeared to inhibit expression of Mcl-1 in parallel with the dephosphorylation of ERK ( Figure 6D ). These observations suggested that TMD1 might negatively regulate the function of the EGF-like domain of TM (TMD2). In fact, TMD1 was shown to inhibit angiogenesis 28 and lipopolysaccharideinduced activation of ERK in macrophages, 29 supporting this hypothesis. Notably, induction of Mcl-1 by TME45 and TME456 was ≈2-fold greater than that mediated by TMD2 ( Figure 6D ). TME123 could act as a negative regulator and inhibit ERK signaling in HUVECs. Further studies are clearly required to verify this hypothesis.
Similarly, another group also showed that EGF-like domain of TM stimulated proliferation of Swiss 3T3 fibroblasts. The investigators used a blocking antibody for EGF receptor, which was not able to hamper the mitogenic effects of the EGF-like domain of TM. 30 These observations suggested that action of TM was not mediated by EGF receptor. The mechanisms by which TMD2 activates ERK/Mcl-1 signaling remain unknown at the present time.
rTM (100 ng/mL, 24 hours) increased levels of p-JNK, another family member of mitogen-activated protein kinase in HUVECs ( Figure 3A) . The phosphorylation of JNK occurred later than that of ERK (figure not shown). JNK is involved in a variety of cellular functions, such as cellular differentiation and proliferation. 31 JNK also mediates apoptosis mediated by a diversity of stress stimuli. For example, we previously showed that activation of JNK/c-Jun signaling mediated either proteasome inhibitor bortezomib or 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis in human lung or prostate cancer cells, respectively, via caspase cascade. 32, 33 SP600125, an inhibitor of JNK, did not affect the expression of Mcl-1 mediated by rTM in HUVECs (figure not shown), suggesting that JNK did not contribute to rTM-stimulated induction of Mcl-1. The roles of activated JNK in HUVECs after exposure to rTM are unclear at the present time.
The maximal plasma concentration of TM in the individuals who received a single dose of rTM 380 U/kg was 1495.4 ng/mL, with a half-life of 28 hours. 34 The present study used 30 to 100 ng/mL rTM, which was clinically relevant. Use of rTM could prevent and cure the potentially lethal complications, such as sinusoidal obstructive syndrome and transplantation-associated microangiopathy after hematopoietic stem cell transplantation, in which endothelial cell injury plays a pathophysiological role. Further studies are clearly required to verify the molecular mechanisms by which TM activates intracelluar signal pathways in endothelial cells. Also, clinical trials are warranted to evaluate the efficacy and safety of rTM in the individuals with endothelial cell damageassociated disorders.
It is important to know that anticoagulation therapy with rTM could potentially augment the risk of hemorrhage in individuals with coagulation abnormality, severe endothelial cell injury, and transfusion-refractory thrombocytopenia, which are clinical features of sinusoidal obstructive syndrome and transplantation-associated microangiopathy. 35 The recombinant TM mutant proteins, such as TME456-I424A, without the capability to modulate coagulation systems would be an attractive cytoprotective agent avoiding hemorrhage. Figure 6 . A, Schematic representation of deletion mutants of human thrombomodulin (TM). TMD1, domain 1 (NH2-terminal domain); TMD2, domain 2 (a domain containing six 6 epidermal growth factor [EGF] domains); TMD3, domain 3 (O-glycosylation site-rich domain); TME456, fourth, fifth, and sixth EGF domains form NH 2 terminus of thrombomodulin (TM); TME45, fourth and fifth EGF domains form NH 2 terminus of TM; *indicates single amino acid substitution. TMD123-I424A and TME456-I424A are not able to bind to thrombin. TMD123-F376L is not able to act as a cofactor for protein C activation. B and C, Purified recombinant TM mutants. COS-1 cells were transiently transfected with various types of TM mutants. After 48 hours, culture supernatants were harvested, and His-tagged TM mutant proteins were purified by using the His-tagged protein purification kit. The purified each mutant TM was detected by Coomassie blue staining (B) and immunoblotting using an anti-V5 antibody (C). Mutant TM proteins were loaded at 1 µg/lane for Coomassie blue staining or 2 µg/lane for immunoblotting. Lane 1, empty vector; 2, TMD1; 3, TMD12; 4, TMD123; 5, TMD123-F376L; 6, TMD123-I424A; 7, TMD2; 8, TME45; 9, TME456; 10, TME456-I424A. D, Cytoprotective effect of TM is independent of activated protein C (APC). Western blot analysis. Top, Human umbilical vein endothelial cells (HUVECs) were exposed to the indicated mutant TM proteins (17.45 fmol). After 48 hours, cells were harvested and subjected to Western blot analysis to monitor the levels of phosphorylated extracellular signal-regulated kinase (p-ERK), extracellular signal-regulated kinase (ERK), and myeloid leukemia cell-1 (Mcl-1). The membrane was sequentially probed with anti-Mcl-1 and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies. Figure represents 1 of the 3 experiments performed independently with identical results. Five micrograms of proteins was loaded to each lane. Bottom, The band intensity was quantified with densitometry, and levels of Mcl-1 were compensated for those of GAPDH. The bar graph summarizes the results of 3 experiments. Empty indicates empty vector. E, A blocking antibody for endothelial protein C receptor (EPCR) and an inhibitor of thrombin do not affect the cytoprotective effects of TM. Western blot analysis. HUVECs were exposed to either recombinant human soluble thrombomodulin (rTM) (30 ng/mL) alone or combination of rTM (30 ng/mL) and anti-EPCR antibody RCR-252 (20 µg/mL) or human recombinant hirudin (5 U/mL). After 24 hours, cells were harvested, and proteins were extracted and subjected to Western blot analysis. The membrane was sequentially probed with the indicated antibodies. Thirty micrograms of proteins was loaded to each lane. The bar graphs summarize results of three experiments.
